Medical network May 8 - two times endowed with new opportunities for children's medicine market, policy support and market orientation, for children's development momentum. And on the market at present with children as the main business of drug firms, because of different proportion of the business sector, only through the company's overall business data, it is difficult to determine the real condition of children's medicine market. 

 

 Eight hot children going through A stock market medicine production enterprises annals, from 2016, there are seven drug firms of revenue of positive growth, but has five net profits have declined. Is the winter really coming so suddenly? Next, we look at the latest reports of the eight pharmaceutical companies to uncover the mystery. 

 

kechuan 

 

In 2016, the pharmaceutical industry made 46.78 billion yuan in revenue, up 24.15 percent from the previous year. Net profit was 934 million yuan, up 36.06 percent over the same period. Mainly because of rush to blue antiphlogistic oral liquid and rabeprazole sodium enteric capsules, infantile loosened up heat grain products such as sales revenue growth, incipient domhke pharmaceutical industry consolidation effect, at the same time the company marketing fees, management fees, financial costs increase caused by the effective control. 

 

 

 

Pediatric class industrial products of the company's main revenue growth is due to pediatric loosened up heat grain sales revenue growth, pediatric loosened up heat particles of sichuan exclusive varieties, pharmaceutical health care b class, attending children wind hot cold. 

 

M Intranet data show that in 2013-2015 China's urban public hospitals, public hospitals at the county level, community center of cities and towns and townships public medical institutions (hereinafter referred to as China) proprietary Chinese medicine paediatric cold medicine brand TOP20 pattern, the children loosened up heat economy sichuan pharmaceutical particles in the first place, market share remained at around 30%. 

 

Hansen 

 

In 2016, Hansen's revenue was 798 million yuan, up 2.22 percent from the previous year. Net profit was 0.85 billion yuan, down 13.40 percent over the same period. 

 

 

 

M Intranet data show that in the past three years, public medical institutions in China traditional pattern of pediatric medicine brand TOP20 anorexia, four soup oral liquid all ranked the first, the market share of more than 30%; And in China's urban retail pharmacies, the drug is the second most common product in 2015, with 14.83 percent of the market. 

 

Hansen pharmaceutical said, will further optimize the product structure, in promoting and selling grind soup and so on four main products at the same time, explore potential products, form product echelon; At the same time, we will increase the marketing input of new products, establish a new product model hospital market, establish a new marketing system, and make a breakthrough in the sales of new products. 

 

Kangzhi pharmaceuticals 

 

The company's revenue in 2016 was 471 million yuan, up 15.06 percent from the same period last year. Net profit was 0.46 billion yuan, down 32.32 percent from the same period last year. 

 

 

 

At present, the company production and operation of a total of more than 30 children's medicine kind, covers the medicine for children in antifebrile series, cold series, anti-infection, phlegm cough, allergy series, diarrhea, and digestion and vitamin, etc. 

 

In 2016, the company's sales of children's drug business grew at a rapid rate of 136.18 percent, more than 300 million yuan. Among them, the children diarrhea with digestive series is the best-selling series in the children's drugs, which accounts for 35.41%, operating income in 2016 operating income of 167 million yuan, up 1365.45% from a year earlier. 

 

Jianmin group 

 

The annual revenue of jianmin group reached 23.64 billion yuan, up by 3.61 percent year on year, and net profit of 0.65 billion yuan, down 24.38 percent year on year. 

 

 

 

In the last two years, the group's paediatrics business has maintained a business revenue of around 290 million yuan, which accounted for 12 percent of the company's total revenue in 2016. The main products include the dragon and the stallion, the children's baotaikang grain, the children's lung and the cough particles. 

 

Dragon bones negundo particles is the exclusive varieties, jianmin group the product is the best-selling products in the retail market, in 2015 China's urban retail pharmacies proprietary Chinese medicine pediatric nutrition dose of medicine to more than 90% of market share in the top 10 no. 1. Pediatric treasure taikang particles is the company in addition a popular type of pediatric medicine, in 2015 China public medical institution proprietary Chinese medicine pediatric cough expectorant drug brand TOP20 ranked eighth in the pattern. The children's lung cough particle is the national secondary Chinese traditional Chinese medicine protection. 

 

Jianmin group said that the current progress of new drug research and development of pediatrics products pediatric kam anti-diarrhea granule, azithromycin (dry suspension agent has obtained the approval documents of clinical, including azithromycin slow-release dry suspension agent for domestic first copy, in addition, the research work has also launched the infantile constipation particles. 

 

yppo 

 

Talc pharmaceutical on children's health in the pharmaceutical industry brand, at the same time in heart cerebrovascular, such as domestic digestive and antitumor drug market the most scale and growth of therapeutic areas, has formed more perfect product layout. The company realized revenue of 18.06 billion yuan in 2016, down 12.56 percent from the same period last year. Net profit was 225.2 million yuan, down 89.86 percent from a year earlier. 

 

 

 

In 2016, the company's paediatric business revenue was just 261 million yuan, down nearly 60%. The company's paediatric series, which is the dominant product in the series, has seen sales drop by more than 52% in 2016, according to the annual report. 

 

Talc pharmaceutical pediatric product variety, in addition to leading products Ding Gui son navel stick, and gastrointestinal drug infantile diarrhea paste, infantile diarrhea stops are scattered, job bud spleen gel and lactic acid bacteria, respiratory medicine qing pharynx children antipyretic oral liquid, the young child to cough and gasp the spirit oral liquid, particle, pediatric children lungs heat to cough and gasp the acetaminophen Huang Na sensitive particles, nutrition supplements zinc gluconate oral liquid, and calcium gluconate oral liquid, etc. 

 

China water crane 

 

In 2016, the company realized its main business revenue was 53.67 billion yuan, up 8% year on year, and net profit of 71.4 million yuan, up 8% year on year. The company accelerated the transformation of the business and increased the proportion of the non-infusion business income. By the end of the report, the company had more than 60 percent of the revenue from the non-infusion business, up 7 percent from 2015. 

 

 

 

, CRC double crane field of pediatric drug use in 2016 increased 18.59%, revenue exceeded 258 million yuan, the core product had made Sue, sales revenue growth of 43% year-on-year. 

 

Cosette made Sue (bovine pulmonary surfactant for injection) is exclusive to CRC double crane products, according to m, according to data from the network structure of public medical chemical medicine pattern in China in 2015 other respiratory preparation brand ranked second in the TOP20, in the last three years of market share remained at about 25%. 

 

During the period of the report, the propaeditic drug was used for the use of caffeine injection of citric acid and 4 classes, which were used to treat the primary breathing suspension of premature infants. 

 

Sunflower pharmaceuticals 

 

Sunflower pharmaceutical medicine for children product main layout, the digestive system drugs, breathing cold medication, medication, rheumatism bone disease of department of gynaecology drugs, cardiovascular drugs, six big products group field. In 2016, the company made 33.64 billion yuan in revenue, up 10.83 percent from a year earlier and net profit of 303 million yuan, down 1.17 percent from a year earlier. 

 

The children's lung cough and asthma is a single product sold by sunflower pharmaceuticals, which is also a key product of the company's children's medicine. Sunflower pharmaceutical co., said in 2017, children lungs heat to cough and gasp the oral liquid, infantile Indian bay leaf antifebrile grain, infantile righting decongestion stilbene welcome this particles will become the company drugs "golden triangle" of the child, have become a little sunflower children big variety in the field of medicine. 

 

Currently, there are five children in the pharmaceutical industry in sunflowers. 

 

The children's scutellaria scutellaria, a drug that is used in the treatment of the cold of foreign children, is now in preparation for clinical trial. 

 

Gold wood particles pediatric pneumonia, 6 classes, for traditional Chinese medicine used in children because of the six exogenous, plague poison, toxic heat accumulate lung, qi depression indicates, sputum XuanSu disadvantage caused by fever, cough, wheeze, shortness of breath, be agitated, symptoms such as coughing up phlegm; By viral infection, or mixed infection by the virus and bacteria to pediatric pneumonia and bronchitis, upper respiratory tract infection disease, clinical trials now preparatory work. 

 

Children's vitamin D, which is used in children's calcium supplements, is currently being reviewed by CFDA. 

 

The children's calcium carbonate D3 granule, which is used to supplement children's calcium with 6 new drugs, is currently in the CFDA professional review. 

 

Ibuprofen oral solution for the 6 class new medicine, medicine for children common cold or influenza caused by fever, also used to relieve mild to moderate pain, children at present in the CFDA professional review. 

 

sandahua 

 

Pharmaceutical business is mainly composed of subsidiary dyne pharmaceutical management, pharmaceutical products in 2016 operating income is 880 million yuan, up 27.01% from a year earlier, the business account for 57% of the company's total revenue, gross margin of 87.17%. 

 

Dyne pharmaceutical products are mainly involved in the children's medicine, food and supplies, children's medicine include vitamin AD drops, compound calcium carbonate effervescent granules, licorice zinc particles, azithromycin granules, rifampicin and smoothie Ming dry suspension agent, two sh succinic acid capsules, etc. 

 

The dyne pharmaceutical industry is currently in the process of drug registration project for children all drug types: more Pan Li ketone mixed suspension clinical trials have been carried out, completed in 2016 BE research. During the period of the report, the new coke release was obtained, and the ground chlorine was given to the clinical trial of the oral solution, the dipperin and the granule. To obtain the notification of the notification of the two products of pedomodore oral liquid and montmorillonite. In addition, there are five research and development projects in the line review, including the dextran iron particles, left cetirizine hydrochloride oral drops, loratadine, chewable calcium carbonate D3 (Ⅱ), vitamin D drops. 

 

Thanks to the preferential review, the enterprise r&d layout is strengthened 

 

Of the eight children drug firms have announced six children medicine sector revenue situation: economic sichuan pharmaceutical rose 35.92%, Hansen pharmaceutical rose 1.06%, Kang Zhi pharmaceutical rose 136.18%, jianmin group rose 0.51%, China resources double crane rose 18.59%, big trend is still rising. The company is down 59.54 percent, due to the company's aggressive marketing channel reform, which is influenced by the marketing channel reform. 

 

Research and development, jianmin group, China resources double crane, sunflower pharmaceutical dyne pharmaceutical dahua hill's subsidiaries have multiple at different stages of research products entered the approval process. On the one hand is to give thanks to priority review policy support, on the other hand also shows the enterprise bullish on children's development in the field of medicine, continuously intensify development layout. 

 

As a whole, the market for children's medicines is growing in a more professional way, with the growing maturity of breed innovation and promotion. As the production and operation of enterprises, are now in a constant state of rectification and improvement, they are trying to think about two questions: how to divide the good its own resources to build more powerful children medicine production chain, as well as research and development to produce more competitive products. We may as well be patient and wait for a new situation in the market for children's medicine in China.